Aleksandra A. Nikonova
Research Subjects
Aleksandra A. Nikonova has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Musa Rakhimovich Khaitov
National Research Center Institute of Immunology FMBA of Russia Moscow Russian Federation
24 shared publications - Igor P. Shilovskiy
National Research Center Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russia
10 shared publications - Vitaliy Vasilievich Zverev
I.I. Mechnikov Institute of Vaccines and Sera, 105064 Moscow, Russia
10 shared publications - Dmitry Anatolievich Kudlay
Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia
9 shared publications - Rudolf Valenta
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
6 shared publications - Sebastian L. Johnston
National Heart and Lung Institute, Imperial College London London UK
6 shared publications
Latest Publications
- 1 April 2026
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 26 (1)
Chikungunya virus-specific pre-existing T cell responses in naïve donors and B cell epitopes in seropositive individuals and experimentally infected mice
INTRODUCTION. Chikungunya virus (CHIKV) poses a major public health challenge in endemic regions due to the lack of specific preventive measures and effective antiviral therapies. Understanding and identifying viral epitopes through rigorous research directly supports the development of more effective next-generation vaccines. AIM. This study aimed to investigate the presence of pre-existing CHIKV-specific T cell memory in unexposed individuals and identified the B cell epitopes targeted in both seropositive donors and CHIKV-infected murine models. MATERIALS AND METHODS. Peripheral blood from 34 healthy volunteers and sera from four CHIKV-seropositive individuals, as well as from BALB/c mice immunized with a non-lethal CHIKV strain, were analyzed to assess Tand B-cell responses. Five synthetic peptides (21–29 aa) derived from nsP2, nsP3, nsP4, and E2 proteins were selected using the immunogenicity prediction algorithm from the Immune Epitope Database and synthesized to encompass predicted epitopes with flanking residues. Peripheral blood mononuclear cells from unexposed donors were stimulated with peptides (1.2 µg/mL), and CD4+/CD8+ T cell proliferation was evaluated by carboxyfluorescein succinimidyl ester (CFSE)-based flow cytometry. Human and mouse sera were tested for peptide-specific IgG by enzyme-linked immunosorbent assay (ELISA). Epitope localization was visualized on 3D protein models using UCSF ChimeraX software and web server I-TASSER. RESULTS. T cell proliferation assays with CFSE labeling revealed preexisting CD4+, but not CD8+, T cell responses to peptides from nonstructural (nsP2–4) and structural (E2) CHIKV proteins in seronegative donors ( P P CONCLUSIONS. Our findings indicate the presence of preexisting CD4+ T cell responses in antigen-naïve individuals and underscore the importance of experimentally validating in silico –predicted epitopes for advancing serological diagnostics and vaccine development.
- 1 April 2026
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 26 (1)
Chikungunya virus-specific pre-existing T cell responses in naïve donors and B cell epitopes in seropositive individuals and experimentally infected mice
INTRODUCTION. Chikungunya virus (CHIKV) poses a major public health challenge in endemic regions due to the lack of specific preventive measures and effective antiviral therapies. Understanding and identifying viral epitopes through rigorous research directly supports the development of more effective next-generation vaccines. AIM. This study aimed to investigate the presence of pre-existing CHIKV-specific T cell memory in unexposed individuals and identified the B cell epitopes targeted in both seropositive donors and CHIKV-infected murine models. MATERIALS AND METHODS. Peripheral blood from 34 healthy volunteers and sera from four CHIKV-seropositive individuals, as well as from BALB/c mice immunized with a non-lethal CHIKV strain, were analyzed to assess Tand B-cell responses. Five synthetic peptides (21–29 aa) derived from nsP2, nsP3, nsP4, and E2 proteins were selected using the immunogenicity prediction algorithm from the Immune Epitope Database and synthesized to encompass predicted epitopes with flanking residues. Peripheral blood mononuclear cells from unexposed donors were stimulated with peptides (1.2 µg/mL), and CD4+/CD8+ T cell proliferation was evaluated by carboxyfluorescein succinimidyl ester (CFSE)-based flow cytometry. Human and mouse sera were tested for peptide-specific IgG by enzyme-linked immunosorbent assay (ELISA). Epitope localization was visualized on 3D protein models using UCSF ChimeraX software and web server I-TASSER. RESULTS. T cell proliferation assays with CFSE labeling revealed preexisting CD4+, but not CD8+, T cell responses to peptides from nonstructural (nsP2–4) and structural (E2) CHIKV proteins in seronegative donors ( P P CONCLUSIONS. Our findings indicate the presence of preexisting CD4+ T cell responses in antigen-naïve individuals and underscore the importance of experimentally validating in silico –predicted epitopes for advancing serological diagnostics and vaccine development.
- Open Access
- 2 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8517
Aqueous Dispersion of Unmodified Fullerene C60: Stimulation of Hair Growth and Study of a New Molecular Target for Interaction
Hair loss (alopecia) is a common disorder caused by an interruption in the body’s cycle of hair production. This pathology negatively affects the psychoemotional state of patients and significantly reduces their quality of life. The currently available medical treatments (including minoxidil therapy) are effective in arresting the progression of the disease; however, they allow only partial regrowth of hair at best. A significant clinical result occurs only with regular drug use. There is still great interest in finding new drugs for the treatment of alopecia. In this study, we aimed to examine the effect of an aqueous dispersion of unmodified fullerene C60 (ADF) on hair growth. ADF, produced by a unique technology, is biocompatible and non-toxic. Nu/nu mice were subcutaneously injected (2 μg/animal) every two days for a period of 11 days with ADF and, for control purposes, with phosphate-buffered saline (PBS). It was shown that ADF stimulated hair growth. Histological analysis of the nu/nu mice skin areas showed that animals treated with ADF had significantly more (about twice as many) hair follicles in the anagen phase compared to mice treated with PBS. The effect on hair growth persisted even after discontinuation of ADF administration. Analysis of gene expression demonstrated that ADF affected the Wnt-signaling pathway, increased the expression of the Wnt10b (wingless-type Mouse Mammary Tumor Virus integration site family, member 10B) factor, angiogenetic factors, and downregulated tumor necrosis factor-alpha levels. We propose that the mechanism of ADF action is likely related to its ability to attract macrophages to the hair follicle microenvironment and promote their polarization to the M2 phenotype. In addition, using molecular modeling, we tried to substantiate our hypothesis about the interaction of ADF with the adenosine A2A receptor, which may cause a decrease in tumor necrosis factor-alpha production. Thus, ADF may become a promising drug for the development of new approaches to the treatment of alopecia associated with immune disorders.
- 2 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8517
Open AccessAqueous Dispersion of Unmodified Fullerene C60: Stimulation of Hair Growth and Study of a New Molecular Target for Interaction
Hair loss (alopecia) is a common disorder caused by an interruption in the body’s cycle of hair production. This pathology negatively affects the psychoemotional state of patients and significantly reduces their quality of life. The currently available medical treatments (including minoxidil therapy) are effective in arresting the progression of the disease; however, they allow only partial regrowth of hair at best. A significant clinical result occurs only with regular drug use. There is still great interest in finding new drugs for the treatment of alopecia. In this study, we aimed to examine the effect of an aqueous dispersion of unmodified fullerene C60 (ADF) on hair growth. ADF, produced by a unique technology, is biocompatible and non-toxic. Nu/nu mice were subcutaneously injected (2 μg/animal) every two days for a period of 11 days with ADF and, for control purposes, with phosphate-buffered saline (PBS). It was shown that ADF stimulated hair growth. Histological analysis of the nu/nu mice skin areas showed that animals treated with ADF had significantly more (about twice as many) hair follicles in the anagen phase compared to mice treated with PBS. The effect on hair growth persisted even after discontinuation of ADF administration. Analysis of gene expression demonstrated that ADF affected the Wnt-signaling pathway, increased the expression of the Wnt10b (wingless-type Mouse Mammary Tumor Virus integration site family, member 10B) factor, angiogenetic factors, and downregulated tumor necrosis factor-alpha levels. We propose that the mechanism of ADF action is likely related to its ability to attract macrophages to the hair follicle microenvironment and promote their polarization to the M2 phenotype. In addition, using molecular modeling, we tried to substantiate our hypothesis about the interaction of ADF with the adenosine A2A receptor, which may cause a decrease in tumor necrosis factor-alpha production. Thus, ADF may become a promising drug for the development of new approaches to the treatment of alopecia associated with immune disorders.
- 2 December 2023
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 20 (4) , 387-401
Cationic peptides as promising compounds for the treatment of bacterial complications in atopic dermatitis: Antibacterial activity assessment
BACKGROUND: The decrease in the effectiveness of antibiotics against the background of resistance of microorganisms aggravates the therapy of atopic dermatitis complicated by bacterial infection and actualizes the development of new antimicrobial agents. AIM: To develop, synthesize, and evaluate the antibacterial activity of cationic peptides and an aqueous solution of fullerene C60 to create drugs based on them that will have a spectrum of biological activity, including anti-inflammatory, antiallergic, and antibacterial activities. MATERIALS AND METHODS: This study analyzed the developed linear and dendrimer cationic peptides, whose structure was confirmed by matrix-assisted laser desorption ionization–time of flight mass spectrometry. An aqueous solution of fullerene C60 was obtained using a uniquely developed and patented technology. Antibacterial activity was assessed by diffusion into agar using disks (screening) and serial dilution, which was used to determine the minimum bactericidal concentration of the studied compounds. RESULTS: Moreover, 42 cationic peptides with various structures were developed and synthesized. The molecular weight of the peptides did not exceed 5,000 Da. They contained 7–25 amino acids with charges from +5 to +16. Screening was carried out through diffusion into agar using disks and revealed 15 peptides that showed activity against Escherichia coli Dh5a. Thus, using the method of counting colonies, the peptides AB-14, AB-17, and AB-18 showed bactericidal activity relative to E. coli Dh5a in concentrations of 0.03, 0.15, and 0.74 mM, respectively, which exceeded that of ampicillin (0.74 mM) several times. Analysis of an aqueous solution of fullerene C60 did not reveal its antibacterial activity. CONCLUSIONS: The antibacterial activity of the resulting peptides makes them promising for the development of antibacterial therapeutic agents.
- 2 December 2023
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 20 (4) , 387-401
Cationic peptides as promising compounds for the treatment of bacterial complications in atopic dermatitis: Antibacterial activity assessment
BACKGROUND: The decrease in the effectiveness of antibiotics against the background of resistance of microorganisms aggravates the therapy of atopic dermatitis complicated by bacterial infection and actualizes the development of new antimicrobial agents. AIM: To develop, synthesize, and evaluate the antibacterial activity of cationic peptides and an aqueous solution of fullerene C60 to create drugs based on them that will have a spectrum of biological activity, including anti-inflammatory, antiallergic, and antibacterial activities. MATERIALS AND METHODS: This study analyzed the developed linear and dendrimer cationic peptides, whose structure was confirmed by matrix-assisted laser desorption ionization–time of flight mass spectrometry. An aqueous solution of fullerene C60 was obtained using a uniquely developed and patented technology. Antibacterial activity was assessed by diffusion into agar using disks (screening) and serial dilution, which was used to determine the minimum bactericidal concentration of the studied compounds. RESULTS: Moreover, 42 cationic peptides with various structures were developed and synthesized. The molecular weight of the peptides did not exceed 5,000 Da. They contained 7–25 amino acids with charges from +5 to +16. Screening was carried out through diffusion into agar using disks and revealed 15 peptides that showed activity against Escherichia coli Dh5a. Thus, using the method of counting colonies, the peptides AB-14, AB-17, and AB-18 showed bactericidal activity relative to E. coli Dh5a in concentrations of 0.03, 0.15, and 0.74 mM, respectively, which exceeded that of ampicillin (0.74 mM) several times. Analysis of an aqueous solution of fullerene C60 did not reveal its antibacterial activity. CONCLUSIONS: The antibacterial activity of the resulting peptides makes them promising for the development of antibacterial therapeutic agents.
Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy
Background: IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome.Methods: We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from the IgE‐binding sites of Bet v 1 and the cross‐reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB‐PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB‐PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB‐PreS and birch pollen extract‐based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.Results: IgE‐binding experiments and basophil activation test revealed the hypoallergenic nature of AB‐PreS. AB‐PreS induced lower T‐cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB‐PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract‐based vaccines. Additionally, immunization with AB‐PreS induced HBV‐specific antibodies potentially protecting from infection with HBV.Conclusion: The recombinant AB‐PreS‐based vaccine is hypoallergenic and superior over currently registered allergen extract‐based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy
Background: IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome.Methods: We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from the IgE‐binding sites of Bet v 1 and the cross‐reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB‐PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB‐PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB‐PreS and birch pollen extract‐based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.Results: IgE‐binding experiments and basophil activation test revealed the hypoallergenic nature of AB‐PreS. AB‐PreS induced lower T‐cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB‐PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract‐based vaccines. Additionally, immunization with AB‐PreS induced HBV‐specific antibodies potentially protecting from infection with HBV.Conclusion: The recombinant AB‐PreS‐based vaccine is hypoallergenic and superior over currently registered allergen extract‐based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
- Open Access
- 29 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8081
Multiplex Lithographic SERS Aptasensor for Detection of Several Respiratory Viruses in One Pot
Rapid and reliable techniques for virus identification are required in light of recurring epidemics and pandemics throughout the world. Several techniques have been distributed for testing the flow of patients. Polymerase chain reaction with reverse transcription is a reliable and sensitive, though not rapid, tool. The antibody-based strip is a rapid, though not reliable, and sensitive tool. A set of alternative tools is being developed to meet all the needs of the customer. Surface-enhanced Raman spectroscopy (SERS) provides the possibility of single molecule detection taking several minutes. Here, a multiplex lithographic SERS aptasensor was developed aiming at the detection of several respiratory viruses in one pot within 17 min. The four labeled aptamers were anchored onto the metal surface of four SERS zones; the caught viruses affect the SERS signals of the labels, providing changes in the analytical signals. The sensor was able to decode mixes of SARS-CoV-2 (severe acute respiratory syndrome coronavirus two), influenza A virus, respiratory syncytial virus, and adenovirus within a single experiment through a one-stage recognition process.
- 29 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8081
Open AccessMultiplex Lithographic SERS Aptasensor for Detection of Several Respiratory Viruses in One Pot
Rapid and reliable techniques for virus identification are required in light of recurring epidemics and pandemics throughout the world. Several techniques have been distributed for testing the flow of patients. Polymerase chain reaction with reverse transcription is a reliable and sensitive, though not rapid, tool. The antibody-based strip is a rapid, though not reliable, and sensitive tool. A set of alternative tools is being developed to meet all the needs of the customer. Surface-enhanced Raman spectroscopy (SERS) provides the possibility of single molecule detection taking several minutes. Here, a multiplex lithographic SERS aptasensor was developed aiming at the detection of several respiratory viruses in one pot within 17 min. The four labeled aptamers were anchored onto the metal surface of four SERS zones; the caught viruses affect the SERS signals of the labels, providing changes in the analytical signals. The sensor was able to decode mixes of SARS-CoV-2 (severe acute respiratory syndrome coronavirus two), influenza A virus, respiratory syncytial virus, and adenovirus within a single experiment through a one-stage recognition process.
- Open Access
Treatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation
Background: Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation MIR 19® (siR‐7‐EM/KK‐46) targeting a conserved sequence in known SARS‐CoV‐2 variants for treatment of COVID‐19. Methods: We conducted an open‐label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID‐19 ( N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization. Results: Patients from the low‐dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of >95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5–7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7–10). No significant clinical efficacy was observed for the high‐dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low‐, high‐dose and control group, respectively. None of them were associated with siR‐7‐EM/KK‐46. Conclusions: siR‐7‐EM/KK‐46, a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID‐19 compared to standard therapy in a randomized controlled trial.
Open AccessTreatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation
Background: Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation MIR 19® (siR‐7‐EM/KK‐46) targeting a conserved sequence in known SARS‐CoV‐2 variants for treatment of COVID‐19. Methods: We conducted an open‐label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID‐19 ( N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization. Results: Patients from the low‐dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of >95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5–7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7–10). No significant clinical efficacy was observed for the high‐dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low‐, high‐dose and control group, respectively. None of them were associated with siR‐7‐EM/KK‐46. Conclusions: siR‐7‐EM/KK‐46, a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID‐19 compared to standard therapy in a randomized controlled trial.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (4)
Additive effect of synthetic small interfering RNAs targeted to respiratory syncytial virus
Аддитивный эффект синтетических малых интерферирующих РНК в отношении респираторно-синцитиального вируса
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (4)
Open AccessAdditive effect of synthetic small interfering RNAs targeted to respiratory syncytial virus
Аддитивный эффект синтетических малых интерферирующих РНК в отношении респираторно-синцитиального вируса
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
Results of clinical trials phases I and II of MIR 19®
Результаты I и II фазы клинических исследований препарата МИР 19
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
Open AccessResults of clinical trials phases I and II of MIR 19®
Результаты I и II фазы клинических исследований препарата МИР 19
- Open Access
- 7 December 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (12)
Allergic sensitization to Mal d 1 without detectable specific serum IgE
- 7 December 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (12)
Open AccessAllergic sensitization to Mal d 1 without detectable specific serum IgE
- Open Access
- 1 November 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (21) , 3854
Lithographic SERS Aptasensor for Ultrasensitive Detection of SARS-CoV-2 in Biological Fluids
In this paper, we propose a technology for the rapid and sensitive detection of the whole viral particles of SARS-CoV-2 using double-labeled DNA aptamers as recognition elements together with the SERS method for detecting the optical response. We report on the development of a SERS-aptasensor based on a reproducible lithographic SERS substrate, featuring the combination of high speed, specificity, and ultrasensitive quantitative detection of SARS-CoV-2 virions. The sensor makes it possible to identify SARS-CoV-2 in very low concentrations (the limit of detection was 100 copies/mL), demonstrating a sensitivity level comparable to the existing diagnostic golden standard—the reverse transcription polymerase chain reaction.
- 1 November 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (21) , 3854
Open AccessLithographic SERS Aptasensor for Ultrasensitive Detection of SARS-CoV-2 in Biological Fluids
In this paper, we propose a technology for the rapid and sensitive detection of the whole viral particles of SARS-CoV-2 using double-labeled DNA aptamers as recognition elements together with the SERS method for detecting the optical response. We report on the development of a SERS-aptasensor based on a reproducible lithographic SERS substrate, featuring the combination of high speed, specificity, and ultrasensitive quantitative detection of SARS-CoV-2 virions. The sensor makes it possible to identify SARS-CoV-2 in very low concentrations (the limit of detection was 100 copies/mL), demonstrating a sensitivity level comparable to the existing diagnostic golden standard—the reverse transcription polymerase chain reaction.